Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2022-03-16 Notice of Dividend Amou…
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
长春百克生物科技股份公司关于2021年度利润分配预案的公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the 2021 annual profit distribution plan of Changchun Baker Biological Technology Co., Ltd. It details the proposed cash dividend per share, the total dividend amount, reasons for the dividend payout ratio being below 30%, and the company's financial and operational context. It also includes the board of directors' meeting resolutions, independent directors' opinions, and supervisory board opinions, all related to the dividend distribution plan. The document is not a full annual report or financial statement but a specific announcement about dividend distribution. This fits the definition of a Notice of Dividend Amount (DIV). The document length is under 5,000 characters and is a standalone announcement, not a full report or certification, so it is not RPA or RNS.
2022-03-16 Chinese
长春百克生物科技股份公司2021年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report" for the year 2021 by Changchun Baike Biotechnology Co., Ltd. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2021, including financial and non-financial internal control defects, their identification standards, and remediation status. The content is focused on internal control evaluation rather than full financial statements or audit opinions alone. It is not an Annual Report (10-K) or Audit Report (AR) but a specialized internal control evaluation report. Given the nature of the document, it fits best under the category of Audit Report / Information (AR), which includes applied accounting principles and results of internal or regulatory stress tests, and internal control reports. The document is substantive and not a mere announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Therefore, the classification is AR with high confidence. FY 2021
2022-03-16 Chinese
长春百克生物科技股份公司公司章程
Governance Information Classification · 95% confidence The document is a detailed company charter or articles of association for Changchun BCHT Biotechnology Co., including chapters on company organization, shareholder rights, board of directors, management, financial accounting, and shareholder meetings. It references Chinese company law and securities regulations, and includes detailed provisions on share issuance, shareholder meetings, board responsibilities, and corporate governance. The content is legal and governance-focused, detailing internal rules and procedures rather than financial results or announcements. It is not an annual report, earnings release, or any financial statement. It is not a proxy statement or voting results announcement. It is a governance document outlining the company's internal rules and governance practices. Therefore, the appropriate classification is Governance Information (CGR). The document length and detail support a high confidence in this classification.
2022-03-16 Chinese
长春百克生物科技股份公司关于聘任证券事务代表的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a securities affairs representative for the company. It details the board meeting resolution approving the appointment, the qualifications of the appointee, and contact information. There is no financial data, no report or presentation content, and no mention of voting results or dividends. This fits the category of Board/Management Information (MANG) as it relates to changes in company management or key personnel.
2022-03-16 Chinese
长春百克生物科技股份公司独立董事对公司2021年度对外担保及关联方资金占用情况的专项说明
Audit Report / Information Classification · 90% confidence The document is a special statement by independent directors regarding the company's external guarantees and related party fund occupation for the fiscal year 2021. It references regulatory guidelines and audit reports but does not contain full financial statements or comprehensive audit results. The document is a standalone explanation focused on specific governance and compliance matters related to external guarantees and related party transactions. It is not a full Annual Report, Audit Report, or Management Report. Given the nature of the content—an independent directors' special statement on specific financial governance issues—it fits best under Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to internal or regulatory checks, excluding full annual reports. FY 2021
2022-03-16 Chinese
长春百克生物科技股份公司关于召开2021年度业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the scheduling and details of a 2021 annual performance explanation meeting (业绩说明会) to be held on March 17, 2022. It describes the meeting format, time, location, participants, and how investors can participate and ask questions. It explicitly states that the company plans to release its 2021 annual report on the same day but does not contain any actual financial data or the report itself. The document is short (1437 characters) and serves as a notice for an upcoming investor presentation event rather than the report or transcript itself. Therefore, it fits best as an Investor Presentation (IP) announcement or related event notice. However, since it is primarily an announcement of the meeting and not the presentation content itself, and given the definitions, the closest classification is Investor Presentation (IP) because it is about a detailed presentation for investors focusing on financials and strategy. Confidence is high due to clear meeting details and purpose.
2022-03-07 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.